Drugs / Interferon β-1a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06510426 | Jul 2024 → Jul 2025 overdue | West-Nile encephalitis | Tel-Aviv Sourasky Medical Center | Recruiting | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 3 | NCT02283853 Comparator | Aug 2014 → Jul 2025 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT00883337 Comparator | Apr 2009 → Sep 2011 | relapsing-remitting multiple sclerosis | Sanofi | Completed | Missed primary |
| Phase 3 | NCT00340834 Comparator | May 2006 → Jul 2011 | relapsing-remitting multiple sclerosis | Novartis | Completed | Met primary |
| Phase 4 | NCT04350684 Background | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon-β 1a | “The intervention drug given will be interferon β1a. Treatment protocol would include 3 subcutaneous injections of IFN-β1a (Rebif), at a dose of 44mcg, given every 48h.” NCT06510426 ↗ |
| Known as | IFN β-1a | “OBJECTIVE: To compare the efficacy, safety, and tolerability of DMF vs intramuscular interferon β-1a (IFNβ-1a) in POMS.” PMID 36169959 ↗ Sep 20222“Treatment protocol would include 3 subcutaneous injections of IFN-β1a (Rebif), at a dose of 44mcg, given every 48h.” NCT06510426 ↗ “IFN β-1a (Avonex)” NCT02283853 ↗ |
| Known as | Rebif | “Treatment protocol would include 3 subcutaneous injections of IFN-β1a (Rebif), at a dose of 44mcg, given every 48h.” NCT06510426 ↗ |
| Route | Intramuscular | “interferon β-1a 30 μg in an intramuscular (im) injection once weekly” NCT00340834 ↗ |